US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.60 against a street estimate of 0.11 — a beat of 445.5%.
Analysts rate Emergent Biosolutions Inc a buy (2 buy, 0 hold, 1 sell out of 3) with an average price target of $11.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.20% |
| Dimensional Fund Advisors, Inc. | 6.00% |
| State Street Corp | 5.71% |
| American Century Companies Inc | 5.40% |
| Vanguard Capital Management, LLC | 4.29% |
| LSV Asset Management | 3.31% |
| Acadian Asset Management LLC | 2.62% |
| Geode Capital Management, LLC | 2.61% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Emergent Biosolutions Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.